| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 02/15/2001 | WO2001010857A1 Compounds having antitumor, antiviral and antibacterial activities |
| 02/15/2001 | WO2001010847A2 Novel integrin receptor antagonists |
| 02/15/2001 | WO2001010842A2 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 02/15/2001 | WO2001010835A1 Antibacterial agents |
| 02/15/2001 | WO2001010834A2 Antibacterial agents |
| 02/15/2001 | WO2001010833A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | WO2001010832A1 Pyrrolidine compounds and their use for treating hyperproliferative diseases and tumor diseases |
| 02/15/2001 | WO2001010831A1 Substituted pyrrolidin-2,3,4-trion-3-oxime derivatives useful as nmda-receptor antagonists |
| 02/15/2001 | WO2001010468A2 Drug-carrier complexes and methods of use thereof |
| 02/15/2001 | WO2001010465A1 Moxifloxacin formulation containing common salt |
| 02/15/2001 | WO2001010459A2 Fish vaccine |
| 02/15/2001 | WO2001010456A2 Peptides that block viral infectivity and methods of use thereof |
| 02/15/2001 | WO2001010455A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | WO2001010454A2 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
| 02/15/2001 | WO2001010439A1 Cyclic amine ccr3 antagonists |
| 02/15/2001 | WO2001010429A2 Long chain n-alkyl compounds and oxa-derivatives thereof and use as antiviral compositions |
| 02/15/2001 | WO2001010427A2 Use of anti-muscarinic agents for treating skin disorders |
| 02/15/2001 | WO2001010413A2 Periodic structures comprising lipids, polyelectrolytes, and structures-inducing soluble oligovalent linkers |
| 02/15/2001 | WO2001010410A1 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof |
| 02/15/2001 | WO2001010408A2 Aqueous pharmaceutical composition containing moxifloxacin or salts thereof |
| 02/15/2001 | WO2001010407A1 Intravaginal clindamycin ovule composition |
| 02/15/2001 | WO2001010387A2 Antiviral therapy use of p-glycoprotein modulators |
| 02/15/2001 | WO2001010383A2 Caspase inhibitors and uses thereof |
| 02/15/2001 | WO2001010381A2 Methods for treating or preventing pain and anxiety |
| 02/15/2001 | WO2000069884A3 Compositions isolated from skin cells and methods for their use |
| 02/15/2001 | WO2000068385A3 Novel nucleic acids and proteins with growth hormone activity |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |
| 02/15/2001 | WO2000063403A3 Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein |
| 02/15/2001 | WO2000062783A3 Ketolide antibacterials |
| 02/15/2001 | WO2000062740A3 Skin care compositions containing combination of skin care actives |
| 02/15/2001 | WO2000061184A3 Dry formulation for transcutaneous immunization |
| 02/15/2001 | WO2000059497A8 Pyrrolidine modulators of chemokine receptor activity |
| 02/15/2001 | WO2000059483A3 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | WO2000053167A3 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| 02/15/2001 | WO2000047198A3 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 02/15/2001 | DE19937656A1 Verwendung von Antithrombin III zur Prophylaxe und Therapie von Erkrankungen The use of antithrombin III for the prophylaxis and treatment of diseases |
| 02/15/2001 | DE19936997A1 Verfahren zur Nutzung von Dendrimeren als Multiplikatoren zur Verabreichung von Photosensibilisatoren Procedures for the use of dendrimers as multipliers for administration of photosensitizers |
| 02/15/2001 | DE19936780A1 Neue Antagonisten von Integrinrezeptoren New antagonists of integrin |
| 02/15/2001 | DE19936719A1 Substituierte 1,5-Dihydropyrrol-2-on-Derivate Substituted 1,5-dihydropyrrol-2-one derivatives |
| 02/15/2001 | DE19936521A1 Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate Substituted pyrrolidine-2,3,4-trione-3-oxime Derivatives |
| 02/15/2001 | CA2382659A1 Dendritic enriched secreted lymphocyte activation molecule |
| 02/15/2001 | CA2381607A1 Glucuronoxylomannan (gxm)-o-acetylhydrolase of cryptococcus neoformans and uses thereof |
| 02/15/2001 | CA2381293A1 Genetically altered dendritic cells transduced with adeno-associated virus (aav), methods of producing said cells and uses thereof |
| 02/15/2001 | CA2381290A1 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 02/15/2001 | CA2381284A1 Fhm, a novel member of the tnf ligand supergene family |
| 02/15/2001 | CA2381215A1 P38map kinase inhibitors |
| 02/15/2001 | CA2381033A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | CA2381008A1 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 02/15/2001 | CA2380973A1 Substituted pyrrolidine-2-3,4-trione 3-oxime derivatives which are active as nmda receptor antagonists |
| 02/15/2001 | CA2380678A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | CA2380647A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 02/15/2001 | CA2379977A1 Novel integrin receptor antagonists |
| 02/15/2001 | CA2379087A1 Antimicrobial histone h1 compositions, kits, and methods of use thereof |
| 02/15/2001 | CA2379052A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | CA2378984A1 Antiviral therapy use of p-glycoprotein modulators |
| 02/15/2001 | CA2378572A1 Intravaginal clindamycin ovule composition |
| 02/15/2001 | CA2378499A1 Cyclic amine ccr3 antagonists |
| 02/15/2001 | CA2378460A1 Peptides that block viral infectivity and methods of use thereof |
| 02/15/2001 | CA2378445A1 Use of anti-muscarinic agents for treating skin disorders |
| 02/15/2001 | CA2378267A1 Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof |
| 02/15/2001 | CA2378032A1 Crystallization and structure determination of staphylococcus aureus udp-n-acetylenolpyruvylglucosamine reductase (s. aureus murb) |
| 02/15/2001 | CA2377422A1 Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof |
| 02/15/2001 | CA2376065A1 Crystallization and structure determination of staphylococcus aureus elongation factor p |
| 02/15/2001 | CA2346063A1 Composition and methods for treatment of hiv infection |
| 02/14/2001 | EP1076062A1 Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors |
| 02/14/2001 | EP1076058A1 $g(b)-LACTAM COMPOUNDS AND PROCESS FOR PRODUCING THE SAME |
| 02/14/2001 | EP1075841A1 Pneumococcal vaccines |
| 02/14/2001 | EP1075840A2 Therapeutic and prophylactic uses of antithrombin III |
| 02/14/2001 | EP1075837A2 Process for the preparation of aqueous formulations for ophthalmic use |
| 02/14/2001 | EP1075537A1 Bacteriophage assay |
| 02/14/2001 | EP1075531A1 Genomic sequences upstream of the coding region of the ifn-alpha2 gene for protein production and delivery |
| 02/14/2001 | EP1075529A1 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 02/14/2001 | EP1075524A2 Attenuated influenza viruses |
| 02/14/2001 | EP1075523A2 Structural proteins of fish pancreatic disease virus and uses thereof |
| 02/14/2001 | EP1075508A2 Enzymatic nucleic acids molecules which modulate the expressions and/or replication of hepatitis c virus |
| 02/14/2001 | EP1075493A2 Dna encoding snorf25 receptor |
| 02/14/2001 | EP1075483A2 Hygromycin a derivatives |
| 02/14/2001 | EP1075467A1 Pyrazole derivatives as p-38 map kinase inhibitors |
| 02/14/2001 | EP1075281A2 Polyol-ifn-beta conjugates |
| 02/14/2001 | EP1075274A2 Immunomodulators for vaccines |
| 02/14/2001 | EP1075273A2 Inhibiton of helicobacter pylori proliferation |
| 02/14/2001 | EP1075261A1 Mycobacterial inhibitors |
| 02/14/2001 | EP1075256A1 Arylhydrocarbon receptor ligand antagonists |
| 02/14/2001 | EP1075186A1 Method of hsv prophylaxis |
| 02/14/2001 | EP0828714B1 Method for making quinolone carboxylic acids or naphthyridine carboxylic acids in free base form |
| 02/14/2001 | CN1284084A Echinocandin derivatives, prepn. method and application as anti-fungal agents |
| 02/14/2001 | CN1284081A Novel macrolides compounds |
| 02/14/2001 | CN1284078A Heterocycilc compounds for inhibition of gastric acid secretion, processes for their prepn. and pharmaceutical compsns thereof |
| 02/14/2001 | CN1284077A Purine derivatives having phosphodiesterase IV inhibition activity |
| 02/14/2001 | CN1284073A 5-(2-imidazolinylamino)-benzimidazole derivatives, their prepn. and their use as alpha-adrenoceptor agonists with inproved metabolic stability |
| 02/14/2001 | CN1284072A Prodrugs of aspartyl protease inhibitors |
| 02/14/2001 | CN1284071A Sulphona mide derivatives as prodrugs of aspartyl protease inhibitors |
| 02/14/2001 | CN1283996A Method/thiol biochdes |
| 02/14/2001 | CN1283995A Antiviral compounds |
| 02/14/2001 | CN1283994A Methods for treatment of neuro-and nephro-disorders and therapeutic toxicities using aminothiol compounds |
| 02/14/2001 | CN1283481A Process for preparing liquid medicine to cure verrucosis and gonorrhea |
| 02/14/2001 | CN1283462A Application of astragalin A in preparing medicinal composition |
| 02/14/2001 | CN1283457A Medicine for treating hircus |
| 02/14/2001 | CN1061869C Treatment preparation for treating hepatitis B |